{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T18:20:08Z","timestamp":1787682008758,"version":"build-2784847793"},"posted":{"date-parts":[[2026,7,3]]},"group-title":"In Review","reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,16]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  Background\n                  <italic>Clostridioides difficile<\/italic>\n                  infection remains a major cause of infectious morbidity and mortality, largely driven by a dysregulated, toxin-mediated host immune response that current pathogen-targeted therapies fail to address. Interleukin-23-driven Th17 responses and subsequent neutrophil activation play a major role in disease severity and intestinal injury. Observational data suggest that targeting this pathway with anti-IL-23 monoclonal antibodies (therapies already used for inflammatory bowel disease, psoriasis) may significantly reduce mortality in these patients.\nMethods\n We conducted a retrospective cohort study of adult patients hospitalized with\n                  <italic>C. difficile<\/italic>\n                  infection using the Epic Cosmos electronic health record database (&gt;\u2009300 million patients across 1,949 healthcare organizations). Propensity score matching (10:1) was used to balance baseline demographic and clinical covariates between patients exposed an available anti-IL-23 monoclonal antibody therapy (ustekinumab, guselkumab, tildrakizumab, risankizumab, mirikizumab) within 90 days prior to diagnosis and unexposed controls. The primary outcome was 30-day all-cause mortality, evaluated using a multivariable Cox proportional hazards regression model, adjusted by ATLAS severity.\nResults\n The propensity-matched cohort included 328 index cases of\n                  <italic>C. difficile<\/italic>\n                  infection exposed to anti-IL-23 within 90-days and 3,155 controls. Anti-IL-23 exposure was associated with a significantly reduced hazard of 30-day mortality (HR 0.341, 95% CI 0.121\u20130.962,\n                  <italic>P<\/italic>\n                  \u2009=\u20090.042). Heterogeneity of treatment effect analysis revealed a statistically significant positive interaction between baseline ATLAS severity and anti-IL-23 efficacy (\n                  <italic>P<\/italic>\n                  \u2009=\u20090.029). No significant difference was observed in 180-day recurrent infection-free survival between groups (HR 0.808, 95% CI 0.514\u20131.27,\n                  <italic>P<\/italic>\n                  \u2009=\u20090.355).\nConclusions\n Antecedent anti-IL-23 therapy is associated with a significant reduction in 30-day mortality following\n                  <italic>C. difficile<\/italic>\n                  infection. These findings support the concept that inhibiting IL-23 mediated inflammation alongside standard anti-\n                  <italic>C. difficile<\/italic>\n                  antibiotics may improve outcomes in\n                  <italic>C. difficile<\/italic>\n                  infection. The significant interaction with baseline severity suggests that the clinical utility of this immunomodulatory therapy may lie in high-risk patient phenotypes. Further prospective studies are warranted to confirm these observations and evaluate the clinical role for IL-23 inhibition in\n                  <italic>C. difficile<\/italic>\n                  infection.\n                <\/p>","DOI":"10.21203\/rs.3.rs-10060050\/v1","type":"posted-content","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:14:58Z","timestamp":1783077298000},"source":"Crossref","is-referenced-by-count":0,"title":["Propensity-Matched Case Control Study of Anti-Interleukin-23 Therapies in Clostridioides difficile Infection"],"prefix":"10.21203","author":[{"given":"Gregory R.","family":"Madden","sequence":"first","affiliation":[{"name":"University of Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennie Z.","family":"Ma","sequence":"additional","affiliation":[{"name":"University of Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamainternmed.2016.9045","article-title":"Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection","volume":"177","author":"Stevens VW","year":"2017","unstructured":"Stevens VW, Nelson RE, Schwab-Daugherty EM, Khader K, Jones MM, Brown KA, et al. Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection. Jama Intern Med. 2017;177:546\u201353.","journal-title":"Jama Intern Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1017\/ice.2023.18","article-title":"Strategies to prevent Clostridioides difficile infections in acute-care hospitals: 2022 Update","volume":"44","author":"Kociolek LK","year":"2023","unstructured":"Kociolek LK, Gerding DN, Carrico R, Carling P, Donskey CJ, Dumyati G, et al. Strategies to prevent Clostridioides difficile infections in acute-care hospitals: 2022 Update. Infect Control Hosp Epidemiol. 2023;44:527\u201349.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhin.2020.09.025","article-title":"Risk of complications and mortality following recurrent and non-recurrent Clostridioides difficile infection: a retrospective observational database study in England","volume":"106","author":"Enoch DA","year":"2020","unstructured":"Enoch DA, Murray-Thomas T, Adomakoh N, Dedman D, Georgopali A, Francis NA, et al. Risk of complications and mortality following recurrent and non-recurrent Clostridioides difficile infection: a retrospective observational database study in England. J Hosp Infect. 2020;106:793\u2013803.","journal-title":"J Hosp Infect"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1002\/imt2.200","article-title":"Understanding host immune responses in Clostridioides difficile infection: Implications for pathogenesis and immunotherapy","volume":"3","author":"Wang L","year":"2024","unstructured":"Wang L, G\u00e1lvez JAV, Lee C, Wu S, Kelly CP, Chen X, et al. Understanding host immune responses in Clostridioides difficile infection: Implications for pathogenesis and immunotherapy. iMeta. 2024;3:e200.","journal-title":"iMeta"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e1029","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults","volume":"73","author":"Johnson S","year":"2021","unstructured":"Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW, Kelly CP, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021;73:e1029\u201344.","journal-title":"Clin Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant","volume":"381","author":"DeFilipp Z","year":"2019","unstructured":"DeFilipp Z, Bloom PP, Soto MT, Mansour MK, Sater MRA, Huntley MH, et al. Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant. New Engl J Med. 2019;381:2043\u201350.","journal-title":"New Engl J Med"},{"key":"ref7","unstructured":"U.S. Food & Drug Administration. Important Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms [Internet]. FDA, Safety & Availability (Biologics). 2019 [cited 2024 Apr 9]."},{"key":"ref8","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.chom.2019.03.003","article-title":"Colitis-Induced Th17 Cells Increase the Risk for Severe Subsequent Clostridium difficile Infection","volume":"25","author":"Saleh MM","year":"2019","unstructured":"Saleh MM, Frisbee AL, Leslie JL, Buonomo EL, Cowardin CA, Ma JZ, et al. Colitis-Induced Th17 Cells Increase the Risk for Severe Subsequent Clostridium difficile Infection. Cell Host Microbe. 2019;25:756\u2013e7655.","journal-title":"Cell Host Microbe"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/infdis\/jit277","article-title":"Role of Interleukin 23 Signaling in Clostridium difficile Colitis","volume":"208","author":"Buonomo EL","year":"2013","unstructured":"Buonomo EL, Madan R, Pramoonjago P, Li L, Okusa MD, Petri WA. Role of Interleukin 23 Signaling in Clostridium difficile Colitis. J Infect Dis. 2013;208:917\u201320.","journal-title":"J Infect Dis"},{"key":"ref10","author":"Abhyankar MM","year":"2020","unstructured":"Abhyankar MM, Ma JZ, Scully KW, Nafziger AJ, Frisbee AL, Saleh MM et al. Immune Profiling To Predict Outcome of Clostridioides difficile Infection. Blaser MJ, editor. Mbio. 2020;11:e00905-20."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2480195","DOI":"10.1080\/19490976.2025.2480195","article-title":"Anti-interleukin-23 treatment linked to improved Clostridioides difficile infection survival","volume":"17","author":"Madden GR","year":"2025","unstructured":"Madden GR, Preissner R, Preissner S, Petri WA. Anti-interleukin-23 treatment linked to improved Clostridioides difficile infection survival. Gut Microbes. 2025;17:2480195.","journal-title":"Gut Microbes"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.ajic.2025.10.014","article-title":"Demographic and regional trends in Clostridioides difficile-related mortality among adults in the United States from 1999 to 2023","volume":"54","author":"Mohib K","year":"2026","unstructured":"Mohib K, Hussain F, Ali B, Munir SU, Ahmed H, Mehmood AT, et al. Demographic and regional trends in Clostridioides difficile-related mortality among adults in the United States from 1999 to 2023. Am J Infect Control. 2026;54:260\u20136.","journal-title":"Am J Infect Control"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections","volume":"116","author":"Kelly CR","year":"2021","unstructured":"Kelly CR, Fischer M, Allegretti JR, LaPlante K, Stewart DB, Limketkai BN, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021;116:1124\u201347.","journal-title":"Am J Gastroenterol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2334-13-148","article-title":"Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy","volume":"13","author":"Miller MA","year":"2013","unstructured":"Miller MA, Louie T, Mullane K, Weiss K, Lentnek A, Golan Y, et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. Bmc Infect Dis. 2013;13:148.","journal-title":"Bmc Infect Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e00676","DOI":"10.1128\/aac.00676-22","article-title":"Validation of Clinical Risk Models for Clostridioides difficile-Attributable Outcomes","volume":"66","author":"Madden GR","year":"2022","unstructured":"Madden GR, Petri WA, Costa DVS, Warren CA, Ma JZ, Sifri CD. Validation of Clinical Risk Models for Clostridioides difficile-Attributable Outcomes. Antimicrob Agents Ch. 2022;66:e00676\u201322.","journal-title":"Antimicrob Agents Ch"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1093\/bioinformatics\/bty315","article-title":"comoRbidity: an R package for the systematic analysis of disease comorbidities","volume":"34","author":"Guti\u00e9rrez-Sacrist\u00e1n A","year":"2018","unstructured":"Guti\u00e9rrez-Sacrist\u00e1n A, Bravo \u00c0, Giannoula A, Mayer MA, Sanz F, Furlong LI. comoRbidity: an R package for the systematic analysis of disease comorbidities. Bioinformatics. 2018;34:3228\u201330.","journal-title":"Bioinformatics"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.21037\/atm.2016.08.57","article-title":"Propensity score method: a non-parametric technique to reduce model dependence","volume":"5","author":"Zhang Z","year":"2016","unstructured":"Zhang Z. Propensity score method: a non-parametric technique to reduce model dependence. Ann Transl Med. 2016;5:7\u20137.","journal-title":"Ann Transl Med"},{"key":"ref18","author":"Borgan \u00d8","year":"2000","unstructured":"Borgan \u00d8, Grambsch M. Springer-, New York; 2000."},{"key":"ref19","volume-title":"Anti-Interleukin-23 Therapy Associated with Improved Clostridioides difficile Infection Survival in a Large Multicenter Cohort","author":"Madden GR","year":"2025","unstructured":"Madden GR, Petri WA. Anti-Interleukin-23 Therapy Associated with Improved Clostridioides difficile Infection Survival in a Large Multicenter Cohort. ClostPath Meeting. Paris, France; 2025."},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1017\/S0950268806007655","article-title":"Accuracy of ICD-9 coding for Clostridium difficile infections: a retrospective cohort","volume":"135","author":"Scheurer DB","year":"2006","unstructured":"Scheurer DB, Hicks LS, Cook EF, Schnipper JL. Accuracy of ICD-9 coding for Clostridium difficile infections: a retrospective cohort. Epidemiol Infect. 2006;135:1010\u20133.","journal-title":"Epidemiol Infect"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10060050\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10060050\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:33:52Z","timestamp":1787679232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-10060050\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":20,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-10060050\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s13099-026-00871-z","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,7,3]]},"subtype":"preprint"}}